Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NASDAQ:NUVL NASDAQ:RGC NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$73.33-0.7%$71.73$14.30▼$82.26$10.40B1.281.51 million shs1.42 million shsNUVLNuvalent$123.25+39.3%$102.91$71.13▼$123.62$6.99B1.15824,819 shs51.70 million shsRGCRegencell Bioscience$20.31-5.0%$27.24$9.39▼$83.60$10.58B1.6591,694 shs89,522 shsTARSTarsus Pharmaceuticals$61.55+3.2%$64.40$38.51▼$85.25$2.57B0.49682,651 shs615,566 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-0.72%+3.54%+0.87%+26.21%+342.55%NUVLNuvalent+39.28%+34.92%+17.07%+23.19%+62.00%RGCRegencell Bioscience-5.05%-12.27%-30.64%-14.16%+2,030,999,900.00%TARSTarsus Pharmaceuticals+3.20%+7.21%+0.56%-11.92%+42.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$73.33-0.7%$71.73$14.30▼$82.26$10.40B1.281.51 million shs1.42 million shsNUVLNuvalent$123.25+39.3%$102.91$71.13▼$123.62$6.99B1.15824,819 shs51.70 million shsRGCRegencell Bioscience$20.31-5.0%$27.24$9.39▼$83.60$10.58B1.6591,694 shs89,522 shsTARSTarsus Pharmaceuticals$61.55+3.2%$64.40$38.51▼$85.25$2.57B0.49682,651 shs615,566 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-0.72%+3.54%+0.87%+26.21%+342.55%NUVLNuvalent+39.28%+34.92%+17.07%+23.19%+62.00%RGCRegencell Bioscience-5.05%-12.27%-30.64%-14.16%+2,030,999,900.00%TARSTarsus Pharmaceuticals+3.20%+7.21%+0.56%-11.92%+42.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.75Moderate Buy$87.8019.73% UpsideNUVLNuvalent 2.55Moderate Buy$133.718.49% UpsideRGCRegencell Bioscience 1.00SellN/AN/ATARSTarsus Pharmaceuticals 2.78Moderate Buy$90.6747.31% UpsideCurrent Analyst Ratings BreakdownLatest TARS, ARWR, RGC, and NUVL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026NUVLNuvalent Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$124.006/9/2026NUVLNuvalent TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/9/2026NUVLNuvalent BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$124.006/9/2026NUVLNuvalent Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$122.856/9/2026NUVLNuvalent Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$124.006/9/2026NUVLNuvalent Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform6/9/2026NUVLNuvalent Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$116.00 ➝ $124.006/9/2026NUVLNuvalent Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$124.006/9/2026NUVLNuvalent Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral6/9/2026NUVLNuvalent HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$124.005/20/2026ARWRArrowhead Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$829.45M12.45$0.12 per share618.59$3.64 per share20.15NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/ARGCRegencell BioscienceN/AN/AN/AN/A$0.01 per shareN/ATARSTarsus Pharmaceuticals$451.36M5.87N/AN/A$8.09 per share7.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$1.63M-$2.15N/AN/AN/A-48.38%-55.09%-18.13%8/6/2026 (Estimated)NUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)RGCRegencell Bioscience-$3.58MN/AN/AN/AN/AN/AN/AN/AN/ATARSTarsus Pharmaceuticals-$66.42M-$1.14N/A21.08N/A-9.02%-14.19%-8.89%8/6/2026 (Estimated)Latest TARS, ARWR, RGC, and NUVL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026RGCRegencell BioscienceN/A-$0.0050N/A-$0.0050N/AN/A5/7/2026Q2 2026ARWRArrowhead Pharmaceuticals-$1.0950-$0.93+$0.1650-$0.93$73.84 million$73.74 million5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/6/2026Q1 2026TARSTarsus Pharmaceuticals-$0.4003-$0.16+$0.2403-$0.16$149.60 million$162.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ARGCRegencell BioscienceN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals1.416.236.23NUVLNuvalentN/A16.1416.14RGCRegencell BioscienceN/A1.41N/ATARSTarsus Pharmaceuticals0.213.743.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%NUVLNuvalent97.26%RGCRegencell Bioscience0.13%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals3.60%NUVLNuvalent5.02%RGCRegencell BioscienceN/ATARSTarsus Pharmaceuticals9.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400140.86 million135.79 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionableRGCRegencell Bioscience10494.49 millionN/AN/ATARSTarsus Pharmaceuticals5043.02 million38.88 millionOptionableTARS, ARWR, RGC, and NUVL HeadlinesRecent News About These CompaniesTarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to Buy at Wall Street ZenJune 6, 2026 | marketbeat.comBNP Paribas Financial Markets Has $29.16 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARSJune 5, 2026 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 3, 2026 | americanbankingnews.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 2, 2026 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesMay 28, 2026 | globenewswire.comLisanti Capital Growth LLC Buys 21,330 Shares of Tarsus Pharmaceuticals, Inc. $TARSMay 24, 2026 | marketbeat.comUBS Group AG Has $5.48 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARSMay 21, 2026 | marketbeat.comTarsus taps John Cena for its latest Demodex blepharitis campaignMay 20, 2026 | fiercepharma.comFTarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS InvestorsMay 20, 2026 | tipranks.comTarsus Pharmaceuticals Inc Ordinary Shares TARSMay 19, 2026 | morningstar.comMJohn Cena hops into the ring to fight demodex blepharitis for Tarsus PharmaceuticalsMay 19, 2026 | mmm-online.comMTarsus Pharmaceuticals, Inc. $TARS Stake Raised by TimesSquare Capital Management LLCMay 19, 2026 | marketbeat.comTarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance RaiseMay 15, 2026 | seekingalpha.comCena was diagnosed with Demodex blepharitis, which he admittedly "didn't even know existed"May 14, 2026 | yahoo.comTarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million AmericansMay 14, 2026 | globenewswire.comAssessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term GainsMay 13, 2026 | finance.yahoo.comTarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS) and Tarsus Pharmaceuticals (TARS)May 11, 2026 | theglobeandmail.comIs It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings?May 11, 2026 | finance.yahoo.comLifeSci Capital Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)May 8, 2026 | theglobeandmail.comTarsus to Participate in Upcoming Investor ConferencesMay 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026The Stars Are Aligning For Apple: Get Ready for $300By Sam Quirke | May 11, 2026TARS, ARWR, RGC, and NUVL Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$73.33 -0.53 (-0.72%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$73.30 -0.03 (-0.04%) As of 06/9/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Nuvalent NASDAQ:NUVL$123.25 +34.76 (+39.28%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$123.17 -0.08 (-0.06%) As of 06/9/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Regencell Bioscience NASDAQ:RGC$20.31 -1.08 (-5.05%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$19.65 -0.66 (-3.25%) As of 06/9/2026 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.Tarsus Pharmaceuticals NASDAQ:TARS$61.55 +1.91 (+3.20%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$60.25 -1.30 (-2.11%) As of 06/9/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
